Literature DB >> 8324733

Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents.

J Bramson1, L C Panasci.   

Abstract

Previous studies of ERCC-1 gene expression levels in chronic lymphocytic leukemia and ovarian carcinoma tumor specimens indicated that increased gene expression may correlate with a lack of response to the alkylating agents, melphalan, and cis-diamminedichloroplatinum (II). In order to demonstrate direct involvement of the ERCC-1 protein in repair of melphalan lesions, the ERCC-1 defective Chinese hamster ovary cell line UV20 was transfected with the human ERCC-1 complementary DNA. Stably transfected UV20 cells demonstrated an increase in resistance to melphalan. Wild type Chinese hamster ovary AA8 cells were then stably transfected with the same complementary DNA. The result was an increase in sensitivity to melphalan. There was no effect on sensitivity to uv light, but the ERCC-1 transfected AA8 cells had an increased sensitivity to cis-diamminedichloroplatinum (II). These results suggest that overexpression of human ERCC-1 may inhibit a pathway specific to the repair of bifunctional DNA damaging agent lesions in AA8 cells. ERCC-1 transfected AA8 cells should be useful in determining the precise role of ERCC-1 in repair of DNA cross-links induced by melphalan.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324733

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Correction of liver dysfunction in DNA repair-deficient mice with an ERCC1 transgene.

Authors:  J Selfridge; K T Hsia; N J Redhead; D W Melton
Journal:  Nucleic Acids Res       Date:  2001-11-15       Impact factor: 16.971

2.  ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs.

Authors:  K W Brookman; J E Lamerdin; M P Thelen; M Hwang; J T Reardon; A Sancar; Z Q Zhou; C A Walter; C N Parris; L H Thompson
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

Review 3.  Biomarkers of head and neck cancer, tools or a gordian knot?

Authors:  Evangeli S Lampri; Georgios Chondrogiannis; Elli Ioachim; Anna Varouktsi; Antigoni Mitselou; Aggeliki Galani; Evangelos Briassoulis; Panagiotis Kanavaros; Vasiliki Galani
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer.

Authors:  Sun Kyung Baek; Si-Young Kim; Jae Jin Lee; Yoon Wha Kim; Hwi Joong Yoon; Kyung Sam Cho
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

5.  Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas.

Authors:  B C Liang; D A Ross; E Reed
Journal:  J Neurooncol       Date:  1995-10       Impact factor: 4.130

6.  cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.

Authors:  M G Ormerod; C O'Neill; D Robertson; L R Kelland; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

7.  Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage.

Authors:  F Larminat; V A Bohr
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

8.  ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.

Authors:  Zhao-Hui Huang; Dong Hua; Xiang Du; Li-Hua Li; Yong Mao; Zhi-Hui Liu; Ming-Xu Song; Xi-Ke Zhou
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

Review 9.  Programming of Cell Resistance to Genotoxic and Oxidative Stress.

Authors:  Ilya O Velegzhaninov; Vitaly A Ievlev; Yana I Pylina; Dmitry M Shadrin; Olesya M Vakhrusheva
Journal:  Biomedicines       Date:  2018-01-02

10.  Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

Authors:  J Matsubara; T Nishina; Y Yamada; T Moriwaki; T Shimoda; T Kajiwara; T E Nakajima; K Kato; T Hamaguchi; Y Shimada; Y Okayama; T Oka; K Shirao
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.